Nanomagnet-based detoxifying machine: An alternative/complementary approach in HIV therapy

Journal of AIDS and Clinical Research

Volumn 5, Issue 5, 2014, Pages

  Seidi, Khaled ^a   Eatemadi, Ali ^a   Mansoori, Behzad ^a   Jahanban Esfahlan, Rana ^a   Farajzadeh, Davoud ^b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AZARBAIJAN SHAHID MADANI UNIVERSITY   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

HIV therapy; Molecularly Imprinted Polymers (MIPs); Nanomagnet Based Detoxifying Machine (NBDM)

Indexed keywords

EID: 84903313267     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000304     Document Type: Review

References (46)

1. Pickrell J (2006) Timeline: HIV and AIDS. New Scientist.
2. Michelle G, Workman C (2009) Clinical manifestations and the natural history of HIV. HIV Management in Australasia, 125-132
3. http://www.who.int/hiv/pub/me/unaids_global_report/en/index.html.
4. Castro A (2005) Adherence to antiretroviral therapy: merging the clinical and social course of AIDS. PLoS Med 2: e338.
5. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739.
6. Levi GC, Vitória MA (2002) Fighting against AIDS: the Brazilian experience. AIDS 16: 2373-2383.
7. Reis AC, Santos EMd, Cruz MMd (2007) A mortalidade por aids no Brasil: um estudo exploratório de sua evolução temporal. Epidemiologia e Serviços de Saúde 16: 195-205.
8. Chiou PY, Kuo BI, Lee MB, Chen YM, Chuang P, et al. (2006) A programme of symptom management for improving quality of life and drug adherence in AIDS/ HIV patients. J Adv Nurs 55: 169-179.
9. Ruiz-Perez I, Olry de Labry-Lima A, Prada-Pardal JL, Rodriguez-Bano J, Causse-Prados M, et al. (2006) Impact of demographic and psychosocial factors on adherence to antiretroviral treatment. Enferm Infecc Microbiol Clin 24: 373-378.
10. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
11. Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58: 640-656.
12. Klastersky J (2006) Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol 18: 316-320.
13. Kang SP, Saif MW (2007) Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol 5: 451-457.
14. Ransohoff RM (2007) Natalizumab for multiple sclerosis. N Engl J Med 356: 2622-2629.
15. Keane J (2005) TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44: 714-720.
16. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, et al. (2006) Anti- TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285.
17. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, et al. (2007) Anti- tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 56: 1754-1764.
18. Major EO (2009) Reemergence of PML in natalizumab-treated patients--new cases, same concerns. N Engl J Med 361: 1041-1043.
19. Aster RH, Bougie DW (2007) Drug-induced immune thrombocytopenia. N Engl J Med 357: 580-587.
20. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, et al. (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242-251.
21. Dixon W, Silman A (2006) Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther 8: 111.
22. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, et al. (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55: 657-670.
23. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, et al. (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28: 3910-3916.
24. Chougnet C, Gessani S (2006) Role of gp120 in dendritic cell dysfunction in HIV infection. J Leukoc Biol 80: 994-1000.
25. Jones MV, Bell JE, Nath A (2000) Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS 14: 2709-2713.
26. Marini A, Harper JM, Romerio F (2008) An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 181: 7713-7720.
27. Bosque A, Planelles V (2009) Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113: 58-65.
28. Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, et al. (2003) Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19: 413-423.
29. Cheong WJ, Yang SH, Ali F (2013) Molecular imprinted polymers for separation science: a review of reviews. J Sep Sci 36: 609-628.
30. Li Y, Yang HH, You QH, Zhuang ZX, Wang XR (2006) Protein recognition via surface molecularly imprinted polymer nanowires. Anal Chem 78: 317-320.
31. Bergmann NM, Peppas NA (2008) Molecularly imprinted polymers with specific recognition for macromolecules and proteins. Progress in Polymer Science 33: 271-288.
32. Bossi A, Bonini F, Turner AP, Piletsky SA (2007) Molecularly imprinted polymers for the recognition of proteins: the state of the art. Biosens Bioelectron 22: 1131-1137.
33. Bures P, Huang Y, Oral E, Peppas NA (2001) Surface modifications and molecular imprinting of polymers in medical and pharmaceutical applications. J Control Release 72: 25-33.
34. Hilt JZ, Byrne ME (2004) Configurational biomimesis in drug delivery: molecular imprinting of biologically significant molecules. Adv Drug Deliv Rev 56: 1599-1620.
35. Berry CC (2005) Possible exploitation of magnetic nanoparticle-cell interaction for biomedical applications. Journal of Materials Chemistry 15: 543-547.
36. Hofmann-Amtenbrink M, Hofmann H, Montet X (2010) Superparamagnetic nanoparticles - a tool for early diagnostics. Swiss Med Wkly 140: w13081.
37. Center RJ, Leapman RD, Lebowitz J, Arthur LO, Earl PL, et al. (2002) Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol 76: 7863-7867.
38. Zhu P, Chertova E, Bess J, Lifson JD, Arthur LO, et al. (2003) Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100: 15812-15817.
39. Curtis BM, Scharnowske S, Watson AJ (1992) Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci U S A 89: 8356-8360.
40. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-767.
41. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, et al. (2007) Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A 104: 19464-19469.
42. Lin G, Baribaud F, Romano J, Doms RW, Hoxie JA (2003) Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol 77: 931-942.
43. Napier KB, Wang ZX, Peiper SC, Trent JO (2007) CCR5 interactions with the variable 3 loop of gp120. J Mol Model 13: 29-41.
44. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, et al. (2010) Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A 107: 1166-1171.
45. Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, et al. (2012) Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomedicine 7: 511-526.
46. Ito R, Machida Y, Sannan T, Nagai T (1990) Magnetic granules: a novel system for specific drug delivery to esophageal mucosa in oral administration. International Journal of Pharmaceutics 61: 109-117.